Clinics in Dermatology
Volume 25, Issue 2 , Pages 165-172 , March 2007

Leprosy

References 

  1. Lockwood DNJ. Leprosy. In:  Burns DA,  Breathnach SM,  Cox NH,  Griffiths CEM editor. 7th ed.. Rook's textbook of dermatology. vol. 2:Oxford: Blackwell Publishing; 2004;p. 29.1–29.21
  2. Global leprosy situation, 2005 . Wkly Epidemiol Rec. 2005;80(34):289–295
  3. Britton WJ, Lockwood DNJ. Leprosy. Lancet. 2004;363:1209–1219
  4. Ridley DS, Jopling WH. Classification of leprosy according to immunity. Int J Lepr. 1966;34:255–273
  5. van Brakel WH, Nicholls PG, Das L, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev. 2005;76:14–34
  6. www.who.int/lep/disease/Eliminate_Leprosy_V8.pdf
  7. Pfaltzgraff RE, Ramu G. Clinical leprosy. In:  Hastings RC editors. Leprosy. 2nd ed.. Edinburgh: Churchill Livingstone; 1994;p. 237–290
  8. Lockwood DNJ, Reid AJC. The diagnosis of leprosy is delayed in the United Kingdom. Q J Med. 2001;94:207–212
  9. Brand PW. Temperature variation and leprosy deformity. Int J Lepr. 1959;27:1–7
  10. Abraham S, Ebenezer GJ, Jesudasan K. Diffuse alopecia of the scalp in borderline-lepromatous leprosy in an Indian patient. Lepr Rev. 1997;68:336–340
  11. Gummer CL, Starley JN, Dawber RP, Pearson JM. The distribution of Mycobacterium leprae in the hair follicle of the eyebrow. Int J Lepr Other Mycobact Dis. 1983;51:205–210
  12. Pakti AH, Baran R. Significance of nail changes in leprosy: a clinical review of 357 cases. Semin Dermatol. 1991;10:77–81
  13. Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev. 1999;70:140–159
  14. Facer P, Mathur R, Pandya SS, et al. Correlation of quantitative tests of nerve and target organ dysfunction with skin immunohistology in leprosy. Brain. 1998;121:2239–2247
  15. van Brakel WH, Khawas IB. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev. 1994;65:350–360
  16. ffytche TJ. The prevalence of disabling ocular complications of leprosy: a global study. Indian J Lepr. 1998;70:49–59
  17. van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev. 1994;65:190–203
  18. Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis. 1999;67:270–278
  19. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol. 1991;84:103–108
  20. Rijal A, Agrawal S, Agarwalla A, Lakhey M. Bullous erythema nodosum leprosum: a case report from Nepal. Lepr Rev. 2004;75:177–180
  21. Moschella SL. Primary diffuse lepromatous leprosy with erythema necrotisans (Lucio phenomenon). Arch Dermatol. 1968;97:593–594
  22. Sehgal V. Contemplative immune mechanism of Lucio phenomenon and its global status. J Dermatol. 1987;14:580–585
  23. Lockwood DNJ, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis. 1999;67:6–12
  24. Ustianowski AP, Lawn SD, Lockwood DNJ. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis. 2006;6:350–360
  25. Faye O, N'Diaye HA, Keita S, et al. High prevalence of non-leprotic hypochromic patches among children in a rural area of Mali, West Africa. Lepr Rev. 2005;76:144–146
  26. Naik RP, Srinivas CR, Rao RV. Thickening of peripheral nerves in neurofibromatosis. Indian J Lepr. 1985;57:876–878
  27. World Health Organisation . Chemotherapy of leprosy for control programmes. In: Tech Rep Ser. Geneva: WHO; 1982;p. 675
  28. Lockwood DNJ, Kumar B. Treatment of leprosy. BMJ. 2004;328:1447–1448
  29. www.clinicalevidence.com
  30. Jopling WH. Complications of treatment with clofazimine (Lamprene: B663). Lepr Rev. 1976;47:1–3
  31. Atkinson AJ, Sheagren JN, Barba Rubio J, Knight V. Evaluation of B.663 in human leprosy. Int J Lepr Other Mycobact Dis. 1967;35:119–127
  32. Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ. 1966;35:165–179
  33. Tomecki KJ, Catalano CJ, Cross H, Newcombe L. An intensive self care training programme reduces admissions for the treatment of plantar ulcers. Lepr Rev. 2001;72:276–284
  34. Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol. 1980;33:244–247
  35. Croft RP, Nicholls PG, Steyerberg EW, et al. A clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up. Lepr Rev. 2003;74:35–41
  36. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: a clinical and epidemiological study—Part 2 Results of steroid treatment. Lepr Rev. 1996;67:104–118
  37. Smith WC, Anderson AM, Withington SG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ. 2004;328:1459
  38. WHO Expert Committee on Leprosy—Fifth Report. In: Tech Rep Ser. Geneva: World Health Organisation; 1977;p. 607
  39. Moreira AL, Kaplan G, Villahermosa LG, et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr Other Mycobact Dis. 1998;66:61–65
  40. Cross H, Newcombe L. An intensive self care training programme reduces admissions for the treatment of plantar ulcers. Lepr Rev. 2001;72(3):276–284
  41. Nicholls PG. Guidelines for social and economic rehabilitation. Lepr Rev. 2000;71:422–465

☆ Dr Walker is supported by grants from LEPRA, the American Leprosy Mission, the Special Trustees of the Hospital for Tropical Diseases, London and the Geoffrey Dowling Fellowship of the British Association of Dermatologists.

PII: S0738-081X(06)00066-6

doi: 10.1016/j.clindermatol.2006.05.012

Clinics in Dermatology
Volume 25, Issue 2 , Pages 165-172 , March 2007

Article Tools

* Image Usage & Resolution